| # | Drug | Count |
|---|---|---|
| 0 | CYCLOPHOSPHAMIDE | 80 |
| 1 | CYCLOPHOSPHAMIDE FOR INJECTION | 80 |
| 2 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 80 |
| 3 | PREDNISONE | 37 |
| 4 | DOXORUBICIN | 33 |
| 5 | ETOPOSIDE | 32 |
| 6 | METHOTREXATE SODIUM | 32 |
| 7 | METHOTREXATE | 28 |
| 8 | RITUXIMAB | 28 |
| 9 | CARBOPLATIN | 24 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | IBRITUMOMAB TIUXETAN | 4 | 0.0026 |
| 1 | ETOPOSIDE PHOSPHATE | 4 | 0.0024 |
| 2 | DACARBAZINE | 15 | 0.0020 |
| 3 | CHLORAMBUCIL | 7 | 0.0018 |
| 4 | MITOXANTRONE HYDROCHLORIDE | 11 | 0.0017 |
| 5 | BLEOMYCIN SULFATE | 16 | 0.0015 |
| 6 | CABAZITAXEL | 4 | 0.0011 |
| 7 | EPIRUBICIN HYDROCHLORIDE | 5 | 0.0008 |
| 8 | BLINATUMOMAB | 6 | 0.0006 |
| 9 | VINCRISTINE SULFATE | 15 | 0.0005 |
| # | Drug class | Count |
|---|---|---|
| 0 | Alkylating Drug [EPC] | 87 |
| 1 | Corticosteroid [EPC] | 76 |
| 2 | Platinum-based Drug [EPC] | 36 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 34 |
| 4 | Topoisomerase Inhibitor [EPC] | 32 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 29 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 28 |
| 7 | Microtubule Inhibitor [EPC] | 27 |
| 8 | BCL-2 Inhibitor [EPC] | 9 |
| 9 | Calcineurin Inhibitor Immunosuppressant [EPC] | 9 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD19-directed Cytolytic Antibody [EPC] | 1 | 0.0012 |
| 1 | Topoisomerase Inhibitor [EPC] | 32 | 0.0004 |
| 2 | Alkylating Drug [EPC] | 87 | 0.0004 |
| 3 | CD22-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 4 | Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] | 1 | 0.0003 |
| 5 | CD33-directed Immunoconjugate [EPC] | 1 | 0.0003 |
| 6 | Asparagine-specific Enzyme [EPC] | 3 | 0.0002 |
| 7 | Radioligand Therapeutic Agent [EPC] | 3 | 0.0002 |
| 8 | Catechol-O-Methyltransferase Inhibitor [EPC] | 1 | 0.0002 |
| 9 | Thrombopoietin Receptor Agonist [EPC] | 3 | 0.0002 |